Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc is a biotechnology company focused on the development of targeted alpha therapy for the treatment of cancer, primarily through its lead product candidate, Iomab-B, for patients with hematologic malignancies.
Business. Actinium Pharmaceuticals Inc (ATNM.K) is a biotechnology company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange under the ticker symbol ATNM. As segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in product-sale activities within the biotechnology and medical research space.
Analyst recommendations
5 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Actinium Pharmaceuticals Inc (ATNM.K) is a biotechnology company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange under the ticker symbol ATNM. As segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in product-sale activities within the biotechnology and medical research space.
Actinium Pharmaceuticals Inc has a strong liquidity position, with cash and equivalents amounting to $86.0 million, which is significantly higher than its total liabilities of $46.0 million, resulting in a current ratio of 8.95. The company's price-to-book ratio of 0.92 suggests that the market value is slightly below the book value, indicating potential undervaluation or investor skepticism about future earnings.
The company is currently unprofitable, with a net loss of $11.4 million and an operating loss of $12.4 million in the latest reporting period. Its return on equity (ROE) is -25.9%, and return on assets (ROA) is -12.6%, both significantly below the industry norms for biotechnology firms, which typically require high R&D investment and long development cycles before achieving profitability.
Actinium Pharmaceuticals Inc operates as a single business segment, with no disclosed geographic diversification in its revenue streams. The company's operations are entirely focused on the development of Iomab-B, a targeted alpha therapy for hematologic malignancies, with no other products currently generating revenue.
The company is in a development phase, with no revenue reported in the latest financial snapshot. Analysts have assigned a mean price target of $5.00, suggesting a potential upside of 290% from the current market price of $1.28. However, the company's operating cash flow of -$15.3 million and free cash flow of -$11.2 million indicate ongoing cash burn, which will need to be managed as it progresses through clinical trials and regulatory approvals.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low debt-to-equity ratio of 0.0, as it has no long-term debt, and its equity base of $43.8 million is supported by a strong cash position. However, the company's reliance on equity financing for future operations could introduce dilution risk if it needs to raise additional capital to fund its development pipeline.
Recent events include the continued development of Iomab-B, with the company preparing for potential regulatory submissions. No recent filings or transcripts indicate significant changes in strategy or operations, and the company remains focused on its core therapeutic area.
- Actinium Pharmaceuticals Inc has a strong liquidity position with $86.0 million in cash and equivalents.
- The company is currently unprofitable, with a net loss of $11.4 million and a negative ROE of -25.9%.
- The company operates as a single business segment with no geographic diversification in revenue.
- Analysts have assigned a mean price target of $5.00, suggesting a potential upside of 290% from the current market price.
- The company has no long-term debt and a low debt-to-equity ratio of 0.0, indicating a conservative capital structure.
Bull / Bear case
Generated · model-assistedAnalysts project 300% upside to a $5.00 mean price target, signaling strong institutional confidence in future value.
The company maintains a healthy current ratio of 6.20, indicating strong short-term liquidity to meet immediate obligations.
Cash conversion metrics rank above the 75th percentile of the biotechnology cohort, suggesting efficient capital utilization relative to peers.
Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for ongoing operations.
Operating income improved by 13.9% year-over-year in the latest period, showing a trend toward reduced operational losses.
The company faces high credit risk, indicating significant concerns regarding its ability to meet long-term financial obligations.
Free cash flow remains deeply negative at -$33.8 million, requiring continuous external capital infusion to sustain operations.
Leverage is classified as high with a debt-to-equity ratio of 5.61, increasing financial vulnerability during market downturns.
In focus — financials by report
Revenue $0.00; Operating income +14,5% YoY.
- ▍Revenue $0.00
- ▍Operating income +14,5% YoY
- ▍Net income +10,7% YoY
- ▍Free cash flow +12,2% YoY
Revenue $90.0k; Operating income +54,8% YoY.
- ▍Revenue $90.0k
- ▍Operating income +54,8% YoY
- ▍Net income +55,6% YoY
- ▍Free cash flow +56,7% YoY
- ▍Net margin -5701.1%
Revenue $0.00; Operating income +39,6% YoY.
- ▍Revenue $0.00
- ▍Operating income +39,6% YoY
- ▍Net income +39,4% YoY
- ▍Free cash flow +40,2% YoY
Revenue $0.00; Operating income -$16.6M.
- ▍Revenue $0.00
- ▍Operating income -$16.6M
Revenue $0.00; Operating income -$7.5M.
- ▍Revenue $0.00
- ▍Operating income -$7.5M
Revenue $0.00; Operating income -$12.6M.
- ▍Revenue $0.00
- ▍Operating income -$12.6M
Revenue $0.00; Operating income -$12.4M.
- ▍Revenue $0.00
- ▍Operating income -$12.4M
Revenue $90.0k; Operating income +13,9% YoY.
- ▍Revenue $90.0k
- ▍Operating income +13,9% YoY
- ▍Net income +11,4% YoY
- ▍Free cash flow +11,1% YoY
- ▍Net margin -37652.2%
Revenue $0.00, −100,0% YoY; Operating income +18,9% YoY.
- ▍Revenue $0.00, −100,0% YoY
- ▍Operating income +18,9% YoY
- ▍Net income +21,7% YoY
- ▍Free cash flow +21,0% YoY
Revenue $81.0k, −92,1% YoY; Operating income −52,2% YoY.
- ▍Revenue $81.0k, −92,1% YoY
- ▍Operating income −52,2% YoY
- ▍Net income −47,9% YoY
- ▍Free cash flow −47,4% YoY
- ▍Net margin -60269.1%
Revenue $1.0M, −10,0% YoY; Operating income −36,6% YoY.
- ▍Revenue $1.0M, −10,0% YoY
- ▍Operating income −36,6% YoY
- ▍Net income −33,3% YoY
- ▍Free cash flow −34,0% YoY
- ▍Net margin -3205.5%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,85 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -33,1M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Actinium Pharmaceuticals Inc Market data — financials · 2026-05-27
- Actinium Pharmaceuticals Inc Market data — analyst estimates · 2026-05-27
- Actinium Pharmaceuticals Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$14M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- Director, Chief Executive Officer · Common StockOther 120 900 @ $1,71$207K · 2025-08-18
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -34.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 25.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 14.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 11.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2023-12-31): 11.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -0.5%Derived (calculated)
- Net margin (FY 2025-12-31): -37,652.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -432.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -65.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -76.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 6.20xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 14.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 5.61xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -29.7%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 845.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 13.9%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Revenue (annual): USD 90KSEC XBRL filing
- Shares outstanding (annual): 31.2MSEC XBRL filing
- Current assets (annual): USD 49.38MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- R&D expense (annual): USD 21.12MSEC XBRL filing
- Operating income (annual): USD -36.25MSEC XBRL filing